

Edgar Filing: Brandt Anna - Form SC 13D

Brandt Anna
Form SC 13D
May 29, 2012

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. ___ /*/)

BODISEN BIOTECH, INC.
(Name of Issuer)

Common Stock, par value \$.01 per share
(Title of Class of Securities)

096892104
(CUSIP Number)

Anna G. Brandt c/o LaRue Brandt
789 Meadowbrook Lane
Chambersburg, PA 17201
abrandt151@yahoo.com
(Name, Address, and Email address of Person Authorized to
Receive Notices and Communications)

May 29, 2012
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the
subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), 13d-1(f) or
13d-1(g), check the following box. ☐

/*/ The remainder of this cover page shall be
filled out for a reporting person's initial filing
on this form with respect to the subject class
of securities, and for any subsequent amendment
containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of
this cover page shall not be deemed to be "filed"
for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject
to the liabilities of that Section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 096892104

1 NAMES OF REPORTING PERSONS

Anna G. Brandt

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐
(b) ☐

Edgar Filing: Brandt Anna - Form SC 13D

3 SEC USE ONLY

4 SOURCE OF FUNDS

PF

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

7 SOLE VOTING POWER

1,849,000

8 SHARED VOTING POWER

0

9 SOLE DISPOSITIVE POWER

1,849,000

10 SHARED DISPOSITIVE POWER

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,849,000

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.6%

14 TYPE OF REPORTING PERSON*

IN

ITEM 1. SECURITY AND ISSUER.

This Schedule 13D relates to the common stock, par value \$0.01 (the "Common Stock"), of Bodisen Biotech, Inc. (the "Issuer").

The address of the Issuer's principal executive office is

Room 2001, FanMei Building
No. 1 Naguan Zhengjie
Xi'an, Shaanxi 710068
People's Republic of China

Edgar Filing: Brandt Anna - Form SC 13D

ITEM 2. IDENTITY AND BACKGROUND.

(a) This statement is being filed by Anna G. Brandt (the "Reporting Person").

(b) The principal address for the Reporting Person is
789 Meadowbrook Lane
Chambersburg, PA 17201.

(c) The Reporting Person is an individual investor.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in the Reporting Person being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of Canada.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

Personal.

ITEM 4. PURPOSE OF TRANSACTION.

I now question whether the big dilution in 2010 Q4 (2,800,000 shares issued for services) was truly in the best interest of current shareholders. Regardless, I hereby demand that the Company repurchase at least 7 million of its shares at a price below 25 cents per share by the end of this year.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

The Reporting Person is an individual investor.
1,849,000 BBCZ shares is 8.6% of the last-reported total outstanding.

The shares were accumulated over several years at an estimated cost-basis of less than \$1.00 per share through open-market purchases.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

Dated as of: May 29, 2012

By: /s/ Anna G. Brandt

Name: Anna G. Brandt